Biological agents in head and neck cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Licitra, L ^a   Locati, L ^a   Bossi, P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BETA CAROTENE; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DEPSIPEPTIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE C; RADIOACTIVE IODINE; SORAFENIB; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR;

ARTICLE; BIOLOGICAL THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; COMORBIDITY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; FACE EDEMA; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; LIVER DYSFUNCTION; LYMPHOCYTE TRANSFER; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; SALIVARY GLAND CANCER; SMOKING HABIT; THYROID CANCER; TRACHEOSTOMY; TREATMENT FAILURE; VIRUS LOAD;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS;

EID: 33749590902     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl235     Document Type: Article

References (44)

1. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-2672.
2. Bonner JA, Harari PM, Giralt J et al. EGFR expression and clinical outcome in head and neck patients treated with radiotherapy with or without cetuximab. Proc Am Soc Clin Oncol 2006; 24: 282S.
3. Yeudall WA, Miyazaki H, Ensley JF et al. Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression. Oral Oncol 2005; 41: 698-708.
4. Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 2879-2882.
5. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
6. Thiery-Vuillemin A, Nguyen T, Pivot et al. Molecularly targeted agents: their promise as cancer chemopreventive interventions. Eur J Cancer 2005; 41: 2003-2015.
7. Dannenberg AJ, Lippman SM, Mann JR et al. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-266.
8. Mayne ST, Lippman SM. Cigarettes: A smoking gun in cancer chemoprevention. J Natl Cancer Inst 2005: 97: 1319-1321.
9. Dassonville O, Formento JL, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-1878.
10. Santini J, Formento JL, Francoual M et al. Characterization, quantification, and putenfial clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13: 132-139.
11. Bentzen SM, Atasoy BM, Daley FM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23: 5560-5567.
12. Ang KK, Berkey BA, Tux et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
13. Eriksen JG, Steiniche T, Askaa J et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58: 561-566.
14. Chung CH, Ely K, Carter J et al. High gene copy number of epidermal growth factor receptor by fluorescence in situ hybridization is frequent in head and neck squamous cell carcinomas and associates with worse recurrence-free survival. Proc Am Soc Clin Oncol 2006; 24: 280S.
15. Cohen EE, Rosen F, Stadler WM et al, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
16. Kane MA, Cohen E, List M et al. Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2004; 23: 507.
17. Wheeler RH, Johnes D, Sharma P et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). Proc Am Soc Clin Oncol 2005; 24: 507S.
18. Wirth LJ, Haddad RI, Lindeman NI et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncoll 2005; 23: 6976-6981.
19. Glisson BS, Blumenschein G, Francisco M et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. Proc Am Soc Clin Oncol 2005; 24: 508S.
20. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncoll 2004: 22: 77-85.
21. Kim ES, Kies M, Sabichi A et al. Phase II Study of Combination Cisplatin, Docetaxel and Erlotinib in Patients with Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC). Proc Am Soc Clin Oncol 2005; 24: 511S.
22. Vokes EE, Cohen EE, Mauer AM et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Proc Am Soc Clin Oncol 2005; 24: 501S.
23. Abidoye OO, Cohen EE, Wong SJ et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc.Clin Oncoll 2006; 24: 279S.
24. Agulnik M, Cohen EE, Cohen RB et al. A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Proc Am Soc Clin Oncol 2006; 24: 296S.
25. Cohen EE, Haraf DJ, Stenson KM et al. Integration of Gefitinib (G), into a Concurrent Chemoradiation (CRT) Regimen Followed by G Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer (HNC) - a Phase II Trial. Proc Am Soc Clin Oncol 2005; 24: 501S.
26. Raben D, Kane MA, Chen C et al. Update on the toxicity and response of a phase I trial of recurrent, daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN). Eur J Cancer 2004; 2 (Suppl): 196.
27. Herchenhorn D, Dias FL, Ferreira CG et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Onool 2006; 24: 298S.
28. Harrington KJ, Bourhis J, Nutting CM et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and-neck (SCCHN). Proc Am Soc Clin Oncol 2006; 24: 293S.
29. Sawides P, Agarwala SS, Greskovich, J et al, Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2006; 24: 291S.
30. Bonner JA Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
31. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
32. Bourhis J, Amand C, Pignon JP et al. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. Proc Am Soc Clin Oncol 2004; 23: 488.
33. Trigo J, Hitt R, Koralewski P et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Proc Am Soc Clin Oncol 2004; 23: 487.
34. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplalin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587.
35. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
36. Chan AT, Hsu MM, Goh BC et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Onool 2005; 23: 3568-3576.
37. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
38. Licitra LF, Locati LD, Potepan P et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study. Proc Am Soc Clin Oncol 2006; 24: 291S.
39. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005; 24: 95-105.
40. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-1904.
41. Cornoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr Virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23: 8942-8949.
42. Wells S, You YN, Lakhani V et al. A phase II trial of ZD6474 in patents with hereditary metastatic medullary thyroid cancer. Proc Am Soc Clin Oncol 2006; 24: 288S.
43. Kloos R, Ringel M, Knopp M et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. Proc Am Soc Clin Onool 2006; 24: 288S.
44. Su YB, Tuttle RM, Fury M et al. A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI-refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience. Proc Am Soc Clin Oncol 2006; 24: 293S.